Medication info
Lyrica Capsule 150mg (Pregabalin)

Lyrica Capsule 150mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›150mg / 1 capsule
Manufacturer / importer
Geonil Biopharm Co., Ltd.
Appearance
A white hard capsule filled with white powder
Packaging
30 capsules/bottle, 100 capsules/bottle
Approval status
Active

MFDS item code 201904257 · Approved 2019.06.19 · Insurance code 073000400

Summary

Main use
Treatment of neuropathic pain, adjunctive treatment of partial-onset seizures in epilepsy, and treatment of fibromyalgia
Who takes it
Adults · Children
Adult dose
This medicine is administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function (see “5. Patients with Renal Impairment”). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The initial dose of this medicine may be 150 mg daily. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: The initial dose of this medicine may be 150 mg daily. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered (see “4. Discontinuation”). 2. Epilepsy Adults: The initial dose of this medicine may be 150 mg daily. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. If necessary, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg daily. The initial dose is 75 mg twice daily (150 mg daily), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg daily). For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Clinical studies have also been conducted at a dose of 600 mg daily; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. 4. Discontinuation Based on current clinical experience, when discontinuing this medicine, it should be tapered gradually over a period of at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is excreted primarily by the kidneys in unchanged form. Since its clearance is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an extra supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalinᵃ Dosing regimen Starting dose (mg/day) Maximum dose (mg/day) ≥60: 150, 600, BID or TID ≥30-<60: 75, 300, BID or TID ≥15-<30: 25-50, 150, QD or BID <15: 25, 75, QD Supplemental dose after hemodialysis: 25, 100, single doseᵇ TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily ᵃ: The total daily dose (mg/day) should be divided as specified in the dosing regimen. ᵇ: Supplemental dose refers to an additional dose administered once. 6. Patients with Hepatic Impairment Dose adjustment is not required in patients with hepatic impairment. 8. Older adults (aged 65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
Children younger than 12 years: Administration is not recommended because there are insufficient safety and efficacy data. Adolescents aged 12-17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Geonil Biopharm Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain, adjunctive treatment of partial-onset seizures in epilepsy, and treatment of fibromyalgia

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to relieve peripheral and central neuropathic pain in adults. It is also used as an adjunct therapy for partial seizures with or without secondary generalized symptoms in epilepsy patients. Additionally, it helps improve symptoms of fibromyalgia. It is effectively used for various nerve-related disorders and symptoms.

How to take

Adult dose

This medicine is administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function (see “5. Patients with Renal Impairment”). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The initial dose of this medicine may be 150 mg daily. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: The initial dose of this medicine may be 150 mg daily. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered (see “4. Discontinuation”). 2. Epilepsy Adults: The initial dose of this medicine may be 150 mg daily. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. If necessary, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg daily. The initial dose is 75 mg twice daily (150 mg daily), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg daily). For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Clinical studies have also been conducted at a dose of 600 mg daily; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. 4. Discontinuation Based on current clinical experience, when discontinuing this medicine, it should be tapered gradually over a period of at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is excreted primarily by the kidneys in unchanged form. Since its clearance is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an extra supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalinᵃ Dosing regimen Starting dose (mg/day) Maximum dose (mg/day) ≥60: 150, 600, BID or TID ≥30-<60: 75, 300, BID or TID ≥15-<30: 25-50, 150, QD or BID <15: 25, 75, QD Supplemental dose after hemodialysis: 25, 100, single doseᵇ TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily ᵃ: The total daily dose (mg/day) should be divided as specified in the dosing regimen. ᵇ: Supplemental dose refers to an additional dose administered once. 6. Patients with Hepatic Impairment Dose adjustment is not required in patients with hepatic impairment. 8. Older adults (aged 65 years and older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

Children younger than 12 years: Administration is not recommended because there are insufficient safety and efficacy data. Adolescents aged 12-17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so patients taking it should be closely monitored for signs of depression, mood changes, or unusual behaviors. Do not take this medication if you are allergic to any of its components or if you have specific genetic lactose intolerance disorders. Diabetic patients should be cautious as weight gain after taking this drug may require adjustments in their blood sugar control medications. If you experience symptoms of angioedema, such as swelling of the face or around the mouth, stop taking the medication immediately and consult a healthcare professional. Older adults may experience increased dizziness or drowsiness while taking this medication, raising the risk of falls. This medication may cause blurred vision or vision changes; if these symptoms occur, you may discontinue the medication. Stopping this medication suddenly may cause withdrawal symptoms such as insomnia, headache, and anxiety, so it should be gradually discontinued after consulting your healthcare provider. Patients with a history of substance abuse are at higher risk for misuse of this medication, so precautions are necessary when taking it. Patients with impaired kidney function may require dosage adjustments, and those with heart disease should also take it carefully. Caution is advised when combining this medication with opioid analgesics due to an increased risk of central nervous system depression. In early pregnancy, there may be a risk of fetal malformation, so pregnant women should avoid this medication or make careful decisions about its use, and women of childbearing age should use effective contraceptive methods. Breastfeeding women should decide carefully about taking this medication as it can be passed through breast milk. This medication may cause dizziness and drowsiness, so caution is needed while driving or operating dangerous machinery. In cases of overdose, symptoms such as confusion, drowsiness, depression, and seizures may occur, and treatment such as dialysis may be necessary if needed. Keep this medication out of the reach of children and avoid transferring it to another container, as this may lead to accidents or deterioration in quality.

Side effects

  • Suicidal ideation
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • edema around the mouth
  • upper airway edema
  • dizziness
  • drowsiness
Show 208 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • thoughts of suicide
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • rhinitis
  • neutropenia
  • increased appetite
  • loss of appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • sexual sensation disorder
  • agitation
  • mood swings
  • emotional lability
  • emotional elevation
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • inability to inhibit
  • apathy
  • dizziness
  • drowsiness
  • ataxia
  • motor coordination disorders
  • balance disorders
  • amnesia
  • attention disorders
  • memory impairment
  • tremors
  • dysarthria
  • sensory abnormalities
  • sensory loss
  • sedation
  • hypersomnolence
  • cognitive impairment
  • nystagmus
  • speech disorders
  • myoclonic jerks
  • diminished reflexes
  • movement disorders
  • psychomotor agitation
  • positional vertigo
  • hypersensitivity
  • burning sensation
  • activity tremor
  • syncope
  • confusion
  • psychomotor retardation
  • olfactory abnormalities
  • loss of taste
  • writing disability
  • blurred vision
  • diplopia
  • loss of peripheral vision
  • visual field disturbances
  • visual field defects
  • photophobia
  • dry eyes
  • eye swelling
  • decreased vision
  • eye pain
  • eye fatigue
  • increased tear production
  • eye irritation
  • mydriasis
  • during vibration
  • changes in depth perception
  • strabismus
  • brightness of vision
  • dizziness
  • auditory hypersensitivity
  • first-degree heart block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal bloating
  • constipation
  • dry mouth
  • abdominal distension
  • excessive salivation
  • gastroesophageal reflux
  • oral sensory impairment
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasm
  • joint swelling
  • myalgia
  • muscle twitching
  • neck pain
  • muscle stiffness
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • reduced urination
  • renal failure
  • erectile dysfunction
  • ejaculation delay
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • breast discharge
  • gynecomastia
  • peripheral edema
  • edema
  • gait abnormalities
  • falling
  • feeling intoxicated
  • sensory disturbances
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • shock
  • anaphylaxis-like symptoms
  • skin and mucous membrane syndrome
  • erythema multiforme
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • state of confusion
  • depression
  • agitation
  • restlessness
  • exacerbation of seizures
  • gastrointestinal disorders
  • tinnitus
  • sleep disorders
  • skin diseases
  • increased BUN
  • hematochezia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air and moisture from entering, and it is recommended to keep it at room temperature between 15 and 30 degrees Celsius. Storing it this way helps maintain the medication’s effectiveness for a long time.

Appearance and packaging

Appearance

A white hard capsule filled with white powder

Package unit

30 capsules/bottle, 100 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.